We are passionate about enabling more convenient solutions for patient centric sampling.

Altasciences is a forward-thinking, mid-size contract research organization strategically located across North-America, offering biopharmaceutical companies of all sizes a proven, flexible approach to preclinical and clinical studies, from lead candidate selection to proof of concept, and beyond. In addition to supporting clinical sites and preclinical testing facilities, their state-of-the-art bioanalytical laboratories provide stand-alone services for both small and large molecules.

With over 25 years of experience, Altasciences has a proven track record for delivering the accurate and precise drug concentrations that sponsors depend upon for successful regulatory submission. Keeping current in the evolving landscape of microsampling solutions for patient-centric healthcare and remote sampling, Altasciences’ evaluation of the Capitainer qDBS found the device straightforward to implement whilst being extremely capable of delivering accurate and precise blood volumes independent of hematocrit level. This allowed all precision and accuracy data for the quantitation of an anti-epileptic drug panel from dried blood spot to readily meet acceptance criteria as recently described at the AAPS, and available here.

For more information visit www.altasciences.com

Molecular MS Diagnostics (MMSD) is in the R&D business for life sciences.  We provide uniquely powerful solutions to our clients, accelerating their analytical and bio-analytical research, empowering them to improve patients lives. MMSD is on a mission to augment research laboratory equipment, space, time, and in-house research expertise to optimize drug development processes while at the same time, saving their clients from middlemen, third parties, and endless approvals to give them the fastest, and most successful outcomes.

Over the past 15 years, we have developed a variety of analytical, bioanalytical and product development services to help life science companies achieve their research goals. Established in 2007, MMSD has expanded  to over 10,000 square feet of lab space filled with ICP-MS, GC-MS and UPLC-MS/MS state of the art equipment.

MMSD has been tasked with developing a newborn screening assay for Lead (Pb) using ICP-MS.  In collaboration with Captainer, the complex blood sample collection and demanding precision challenges for this assay development were over come using the unique qDBS technology solution that has been developed by Capitainer.  We look forward to helping Clinical labs develop multiple bio-analytical metal and /or diagnostics analyte specific screening assays using the different Capitainer devices.

For more information visit www.mmsdiagnostics.com

ProterixBio operates a high-complexity CLIA-certified lab in the Boston area which offers a range of services to support the development and validation of protein biomarker assays. Our CLIA lab houses a highly experienced assay development team that can assist with the optimization of extraction procedures and the validation of analytical methods. Our team is flexible and efficient, and excels at adapting commercially available immunoassay reagent-systems to fit-for-purpose performance in target populations. We have experience across a wide range of therapeutic areas and a diverse range of sample types, including patient-centric samples such as dried blood spots.

In collaboration with Capitainer, we would welcome the opportunity to assist other organizations looking to develop and validate patient-centric immunoassays under appropriate study conditions. Microsampling technologies such as that offered by Capitainer have the potential to improve patient access to accurate biomarker results through superior patient specimen collection, a possibility we look forward to accelerating by bringing our expertise to bear on your bespoke project needs.

High-Complexity CLIA Laboratory – Protein Assay Development Services – Remote Sample Collection % (proterixbio.com)

ThetaBiomarkers created an innovative and technologically advanced research clinical chemistry laboratory for the provision of quality metabolomics-based services for a plethora of biomarkers and drugs regarding health and wellness. We combine deep knowledge of bioanalytical/clinical chemistry, cutting-edge mass spectrometry equipment, and highly qualified expert staff. Our final product includes technologies and unique measurement services, addressed to healthcare professionals, nutritionists, wellness centers, private labs, fitness centers, etc; our service portfolio boasts evidence-based solutions, tailored to the need of our customers, in order to provide a personalized metabolism tracker and personalized wellness/health advises.

In our collaboration with Captainer qDBS, we aim to offer high quality services and give the ability to monitor your metabolic profile in a single blood drop collected at your own leisure. Health monitoring is very important in terms of prevention, particularly since the early detection of metabolic disorder or other diseases can reduce suffering and medical costs.

THETA – Bioanalysis and metabolomics of biological samples (thetabiomarkers.com)

Capitainer AB and AstraZeneca R&D Gothenburg have initiated a research collaboration using a novel device from Capitainer. The new Capitainer^® CF card is capable of producing separated Cell-Free blood from a finger stick at the patients home. The sampling card automatically meters an exact volume of cell free blood and transfer it to a paper disc to produce a dried sample spot similar to dried plasma or serum. Transportation back to the laboratory can be performed at ambient temperature. The objective of this collaboration is to develop protocols for biomarkers relevant to AstraZeneca clinical drug programs based on the novel Capitainer^® CF card , enabling new patient centric sampling solutions to be implemented.

Since 2002, Attana research services and systems have improved their customers’ clinical trial success rates by 4x compared to the industry average. In 2021, they launched their first CE IVD-marked device for novel insights into antibody diagnostics. From a drop of blood (10µl), the AVA^TM laboratory system can both quantify the number of antibodies in a sample as well as determine their neutralizing capacity, in a matter of minutes. On 19th of May 2022, Attana announced an updated CE IVD marking for its AVA^TM SARS-CoV-2 IgG Immunoassay kit. This now includes capillary blood samples using Capitainer®qDBS which enables the technology to be used with self-sampling.

In combination with Capitainer® qDBS, Attana today offers high quality diagnostic analyses in a wider scope of studies than previously possible.

For more information visit www.attana.com

The University of Hertfordshire (UoH) is internationally recognised as the United Kingdom’s leading business-facing University. With a reputation for powering progress in academic and industrial research, we operate a hybrid bioanalytical and pharmaceutical analysis laboratory, with commercial services alongside academic research programmes. The primary focus is on the application of our Waters TQ-S micro and QTof systems to bioanalytical determinations of drugs and biomarkers in a wide range of matrices. The academic interests of UoH lie in the application and development of microsampling technologies.

The partnership with Capitainer focuses on the application of the qDBS technology to respiratory disease management, with the ability to volumetrically sample from a patient as a cornerstone of this. The overarching aim of this collaboration is to achieve an improvement in patient outcomes via monitoring in the remote setting, and driving uptake of novel disease management approaches.

Drug Delivery and Toxicology | Research | Uni of Herts

Harmonising and Unifying Blood Metabolomic Analysis Networks

Capitainer is proud partner of the project with the following aims:

Multidisciplinary consortium
To put together a multidisciplinary consortium with the critical mass to address the limitations in human LC-MS based blood metabolomics, such as result reproducibility and research fragmentation.

Cross-laboratory comparisons
To perform cross-laboratory comparisons to identify the sources of variability in all steps of metabolomics studies: preanalytical, sample preparation, LC-MS analysis, data quality assessment, normalization, statistical processing, pathway analysis and biochemical interpretation. Understanding and solving these issues will lead to improved comparability of results among labs.

Integration and co-evaluation
To promote the field towards effective integration and co-evaluation of data collected by various labs, improving consistency of findings, data reporting, implementation within databases, reproducibility and re-usability of data. Identify bottlenecks in the integration of metabolomics data (pan-cohorts).

Novel blood microsampling techniques
To investigate the implementation of novel blood microsampling techniques in clinical metabolomics and establish workflows for meaningful blood microsample analysis in biomarker discovery and health monitoring.

Proofing
To provide proof of concept on the utility of the developed tools.

Read more about the project on its website: HUMAN doctoral network – Harmonising and Unifying Blood Metabolomic Analysis Networks (human-dn.eu)